CST3 and acute kidney injury: Such follow-up studies should include an a priori power analysis for the biomarkers of interest, involve more homogenous patient groups and incorporate established biomarkers, such as serum cystatin c and serum creatinine, as variables to check against AKI vs. no-AKI status.